F17727

F17727 is an investigational small‑molecule cardiology drug originally developed by Pierre Fabre and subsequently licensed to Boston Pharmaceuticals as a selective potassium channel blocker for the potential treatment of atrial fibrillation. It is positioned as a late preclinical compound aimed at rhythm control in atrial fibrillation by modulating cardiac repolarization through selective blockade of a cardiac potassium channel, although the exact molecular target has not been publicly disclosed. The program has been described as Boston Pharmaceuticals’ first cardiovascular disease candidate and remains in the preclinical to early clinical transition stage, with no approved indications reported to date.[1][2][3][5]